Spore.Bio Gets $23M for Rapid Bacteria Detection | Best free generative ai tools | How does generative ai work | Generative ai advantages and disadvantages | Turtles AI

Spore.Bio, a French startup founded in 2023, has developed an AI-based system that enables the rapid detection of bacteria in consumer products. The company has raised $23 million in a Series A funding round, led by Singular with the participation of international investors. The capital raised will allow it to accelerate the production and distribution of the device, which has already been successfully tested in over 200 factories.

Key points:

• Advanced Technology: Uses AI to analyze bacterial contamination in minutes.
• Strategic Funding: $23 million raised for expansion and industrialization.
• Broad Adoption: Signed contracts with global companies, with particular interest from the United States.
• Diversified Applications: Useful in the food, pharmaceutical, and cosmetics industries.

The need for more efficient tools for consumer product safety control has driven the growth of innovative solutions in the field of microbiology. Traditionally, companies are forced to send samples to specialized laboratories, with waiting times ranging from five to twenty days. This delay can lead to significant risks, both economic and health, and affect the reputation of manufacturers. Spore.Bio has developed a technology that allows control to be carried out directly on the factory floor, providing reliable results in a few minutes. The system is based on a spectroscopic analysis that, thanks to a machine learning algorithm, identifies the presence of bacteria without the need for cultures or PCR tests.

The company has already started commercializing the device, obtaining customers in various industrial sectors. Although specific names have not been disclosed, it is said to be very large companies, approximately half of which are based in the United States. With the funds raised, Spore.Bio plans to increase production and distribute dozens of devices in the coming months, with rapid growth prospects. The interest generated by the technology has led to the creation of a waiting list for future installations.

The $23 million funding round was led by venture capital fund Singular, with participation from Point 72 Ventures, LocalGlobe, No Label Ventures, and other institutional and private investors. This new round follows a previous $8.3 million funding round raised in 2023, bringing the total investment to $31.3 million. The stated goal is to transition from a startup to an established industrial reality, expanding its workforce and evaluating in-house production in France.

Founded by Amine Raji, Maxime Mistretta, and Mohamed Tazi, the startup has a team of experts in microbiology, AI, and optics. The collaboration with the Institut Pasteur provides access to a large biobank of samples to refine analysis models. In addition, Spore.Bio recently acquired Greentropism, a company specialized in spectroscopic analysis, thus strengthening its technical know-how.

The adoption of the technology is not limited to the food sector. The pharmaceutical sector is also showing interest, especially for biological drugs with short expiration dates that require rapid testing. The same goes for the cosmetics industry, where the reduction of preservatives requires more rigorous monitoring of contamination. The need for timely control is reinforced by the 20% increase in product recalls in 2024, with a significant economic impact for the companies involved.

The company will continue to expand with the doubling of its staff by 2025 and the strengthening of its presence in the United States, where it plans to open an operational office.

The technology developed by Spore.Bio is proposed as a reliable and scalable solution to improve microbiological control in industrial processes, responding to the needs of a market that is increasingly attentive to product safety and quality.